AI translation is replacing interpreters in GP care – here’s why that’s troubling

Across GP surgeries and hospitals, as migration increases and health systems strain, doctors are turning to an untested ...

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval ...